Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Abstract EN

Background.

The aims of this study were to analyze the clinical characteristics of SPM in patients with well-differentiated thyroid cancer and to determine the long-term prognosis in patients with double malignancies.

Materials and Methods.

We retrospectively analyzed 2,864 patients with well-differentiated thyroid cancer and a mean age of 44.0±14.4 years.

Of these, 200 (7.0%) were diagnosed with SPM, 115 of which were diagnosed with metachronous SPM.

Results.

Of 2,864 patients, 163 (5.7%) patients died of thyroid cancer and 301 (10.5%) died of any cause by the end of the follow-up period.

Multivariate analysis identified age, SPM, external radiotherapy, TNM stage, and postoperative serum Tg level to be factors independently associated with decreased survival.

Of 200 patients with SPM, 74 (37.0%) died.

In comparison to the anachronous and synchronous groups, the metachronous SPM group had a higher mean age; more advanced tumor, node, and metastasis stage; lower remission rate; higher postoperative radioactive iodide (131I) accumulated dose; a higher proportion of patients who underwent external radiotherapy; and higher thyroid cancer and total mortality rates.

Conclusions.

Patients with well-differentiated thyroid carcinoma and metachronous SPM had worse prognoses compared to patients without SPM.